Hengrui Pharma(SH:600276) Di Yi Cai Jing·2026-01-24 01:26Core Insights - The momentum of Chinese pharmaceutical companies expanding overseas is expected to be sustainable, with strong activity continuing into 2026, although the total number of transactions or amounts may not exceed those of 2025 [1][21]. Group 1: Overseas Licensing Transactions - In January 2025 alone, Chinese pharmaceutical companies completed 10 overseas licensing deals, with a notable transaction between Rongchang Biotech and AbbVie involving an upfront payment of $650 million [1]. - The total number of overseas licensing transactions for Chinese innovative drugs reached 158 in 2025, with a total transaction value of $135.7 billion, marking a ten-year high in both quantity and value [6]. - The upfront payments for overseas licensing transactions in 2025 totaled $7 billion, surpassing the $5.2 billion raised in the primary market by pharmaceutical companies [8]. Group 2: Market Dynamics and Trends - The metabolic field has seen a surge in licensing deals, largely driven by the success of weight-loss drugs from companies like Eli Lilly and Novo Nordisk [4]. - The U.S. remains the primary trading partner for Chinese pharmaceutical companies, accounting for approximately 48% of all licensing transactions over the past decade [12]. - Major pharmaceutical companies are increasingly seeking new pipelines to offset revenue declines from expiring patents, leading to heightened interest in innovative products from Chinese biotech firms [13]. Group 3: Clinical Research and Cost Advantages - China has established a competitive edge in clinical research, with a significantly lower average cost per patient for clinical trials compared to the U.S. ($25,000 in China vs. $70,000 in the U.S.) and a higher patient enrollment rate [16]. - The rapid development of clinical research capabilities in China is expected to continue, further enhancing the country's attractiveness for pharmaceutical partnerships [22]. Group 4: Future Outlook - The interest from multinational pharmaceutical companies in Chinese innovations is expected to remain high, with many companies increasing their presence in China to identify promising assets [20]. - Despite geopolitical tensions, collaboration in innovative drug development between China and the U.S. is strengthening, indicating a logical partnership in addressing healthcare needs [21].